MedTrace Logo

T900607 in Treating Patients With Gastroesophageal Junction Cancer

NCT00054249 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-07-18

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of T900607 in treating patients who have gastroesophageal junction cancer.

Conditions

Interventions

DRUG

T900607

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • University Hospitals Seidman Cancer Center

    lead OTHER

Principal Investigators

  • Joanna M. Brell, MD · Case Comprehensive Cancer Center

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-09-30
Primary Completion
2004-10-31
Completion
2010-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00054249 on ClinicalTrials.gov